News & Events
27 September 2012 - Proveris Scientific Corporation
Proveris Scientific Achieves 10 Consecutive Years of ISO9001 Certification
Marlborough, Mass., 27, September 2012 – Proveris Scientific Corporation ( www.proveris.com ) announced today that the company has received continued certification of its Quality Management System to the ISO9001:2008 standard by TUV Rheinland of North America ( www.us.tuv.com ) marking 10 consecutive years of certification to this prestigious international standard of quality. The latest audit, completed on 27 September 2012, found no deficiencies with the company’s QMS and started the second 3-year cycle of certification for the company.
“This achievement is recognition of our commitment to quality for our global customer base and our longstanding team effort to operate under the ISO9001 quality management system standard”, said Dino J. Farina, President and CEO of Proveris.
19 September 2012 - Proveris Scientific UK Limited
Proveris Scientific UK Limited Grows Its Operations
Chichester, England, 19, September 2012 – (BUSINESS WIRE) Proveris Scientific UK Limited ( www.proveris.com ) announced today that it has taken key steps to enlarge its operations and further execute on its commitment to serving the orally inhaled and spray drug product markets in Europe and Asia.
As one part of its growth initiative, the company has hired a new field service engineer dedicated to supporting and training customers located throughout Europe and Asia. This investment in local resources better positions Proveris to deliver exceptional service to customers who are in the production stages with their respective products.
Proveris has also promoted Mr. Ivan Prince to the position of European Commercial Manager. In this new role, Mr. Prince will apply his extensive knowledge of inhaled drug development to lead Proveris’ product application plans and manage the day-to-day operations of the UK headquarters.
“Ivan joined us after establishing an impressive track record of success within the industry and has demonstrated his expertise and unwavering commitment to excellence each day since,” said Dr. Zachary Pitluk, Chief Commercial Officer of Proveris Scientific Corporation and a Director of Proveris Scientific UK Limited. “We are pleased to announce his promotion and the integral part he will play in helping the company continue to grow the orally inhaled and spray drug product market across the globe.”
In addition to building upon its local team, the company has dedicated financial resources to expanding its training center and repair capabilities. Proveris will provide a hands-on support facility for its European and Asian customer base by installing a variety of the company’s industry leading instrument platforms at the UK headquarters office by the end of this year.
“We have experienced a significant increase in business from European and Asian customers seeking support for their growing markets. Our UK expansion is crucial to providing the high quality of service and world-class support that each of our customers has come to rely upon,” said Mr. Dino Farina, CEO of Proveris Scientific Corporation and a Director of Proveris Scientific UK, Limited. “We are proud partners of established companies like Malvern Instruments Ltd. and Aptar Pharma , and we look forward to ensuring that our customers continue to gain the greatest return on their investments in our solutions.”
About Proveris Scientific UK Limited
Proveris Scientific UK Limited is a wholly-owned subsidiary of Proveris Scientific Corporation. Proveris streamlines complex development and release testing processes of orally inhaled pharmaceutical and nasal drug products by providing complete solutions that reduce overall lab testing time by at least 100-fold compared to manual analysis. Since its inception in 1995, the company has deployed its solutions at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’ solutions are used by the FDA and the pharmaceutical industry to set testing standards and generate robust data for their respective applications. Proveris is certified to ISO 9001:2008 by TUV Rheinland of North America and has more than 20 patents on its technology issued in United States, Europe and Asia. For more information, please visit www.proveris.com .
Press Contact:
Proveris Scientific Corporation
Zach Pitluk, PhD.
Chief Commercial Officer
508-460-8822 Ext. 7634
zpitluk@proveris.com
12 October 2010 - Proveris Scientific Corporation
October 12, 2010 07:00 AM Eastern Daylight Time
Proveris Issues the Following Statement on Pivotal Federal Court Ruling Finding InnovaSystems, Inc. in Contempt
~Supplier of Widely Used Aerosol Inhaler & Spray Testing Equipment Violated 2007 Injunction~
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Proveris Scientific today issued the following statement:
Judge William G. Young, United States District Court for the District of Massachusetts, has ruled that InnovaSystems, Inc. (“Innova”) is in contempt of court for violating the court’s permanent injunction entered in May 2007. The court rejected all of Innova’s arguments that its supposedly new equipment, currently known as the Aerosol Drug Spray Analyzer (ADSA), is materially different from the already enjoined Optical Spray Analyzer (OSA) equipment. The court concluded that Innova’s spray pattern and plume geometry equipment infringes Proveris Scientific Corporation’s United States patent 6,785,400.
The finding of contempt is noteworthy. Contempt rulings for violations of permanent injunctions entered in patent infringement cases are rare. Courts are cautious about finding a party in contempt because, when contempt is found, the enjoined party is subject to sanctions to vindicate the affront to the court’s authority.
This contempt finding also means that Innova customers who purchased the ADSA equipment purchased patent infringing equipment that Innova was prohibited by the court from making, using, exporting, or selling.
“We are surprised and saddened that Innova has persisted in selling their infringing system,” said Dino Farina, Founder and CEO of Proveris. “Our intellectual property portfolio is strong and we will continue to protect it.”
Proveris plans to request the court to enter a sanction comprised of monetary and injunctive relief, including the court's enforcement of the provisions of the injunction prohibiting Innova from providing any maintenance or service on any products sold in contempt of its injunction.
History of the Litigation:
After finding that Innova’s OSA infringes 9 of the 13 claims in Proveris’s 6,785,400 patent, in May 2007 the court entered a permanent injunction that prohibits Innova, its officers, employees, directors, agents, lawyers, and all persons acting in concert with them from:
- Making the OSA
- Using [i.e. feasibility testing, validation testing] the OSA
- Selling the OSA
- Offering for sale [ i.e. quotations] the OSA
- Exporting the OSA out of, or importing the OSA into, the U.S.
By its contempt order, the court found that Innova violated the permanent injunction by engaging in one or more of the proscribed activities in connection with the spray pattern and plume geometry equipment it has made, marketed, used, sold, and exported since entry of the permanent injunction.
Contact:
Proveris Scientific Corporation
Zach Pitluk, PhD.
Chief Commercial Officer
508-460-8822 Ext. 7634
zpitluk@proveris.com
4 November 2009 - Merck and Schering-Plough Complete Merger
3 November 2009 - Merck and Schering-Plough Complete Merger. Merck & Co., Inc . announced completion of its merger with Schering-Plough Corporation as of 3 November 2009. Click here for the full press release from Merck & Co., Inc.
7 September 2009 - Meda Pharmaceuticals, Inc. has expanded rights for azelastine and fluticasone combination. Cliick here for the full press release from Meda Pharmaceuticals, Inc.
2 September 2009 - Meda Pharmaceuticals, Inc. receives FDA Approval of New ASTEPRO(R) (azelastine HCl) Nasal Spray 0.15%, the First and Only Once-Daily Nasal Antihistamine. Click here for the full press release from Meda Pharmaceuticals, Inc.
4 August 2009 - Par Pharmaceutical reports successful launch of NasCobal, Vitamin B12 nasal spray. Click here for the full press release from Par Pharmaceutical .
21 July 2009 - Proveris Scientific Corporation
21 July 2009 - Valois and Pfeiffer Adopt Proveris's Complete Solution - Proveris Scientific Corporation announced today the adoption by Valois Pharma and Ing. Erich Pfeiffer GmbH - leading pump and valve manufacturers in the pharmaceutical industry - of its complete solution for spray analysis and release testing. Proveris's complete solution incorporates an instrument service plan, software licensing, and software support and maintenance.
"Together with Proveris's instruments, the complete solution provides the scalability we need to perform robust, high through-put product testing," said Salim Haffar, President of Valois Pharma.
"We value the relationship with Valois Pharma and Pfeiffer," said Zach Pitluk, Vice President of Commercialization at Proveris Scientific Corporation, "because it allows us to support many current and future OINDP (Orally Inhaled and Nasal Drug Products) projects. Proveris respects the technology and innovativeness of Valois Pharma and Pfeiffer in the OINDP marketplace and looks forward to providing them with complete solutions for spray characterization and release testing."
About Proveris Scientific Corporation
Proveris Scientific streamlines complex development and release testing processes of pharmaceutical spray products by providing complete solutions that reduce overall lab testing time by at least 100 fold when compared to manual analysis. Proveris's complete solutions incorporate the cGMP-enabled Viota ® informatics platform to manage and analyze data; the pioneering SprayVIEW ® instrument for robust, FDA accepted spray pattern and plume geometry analysis; and the robotic Indizo ® instrument for walk-away, highly reproducible shot weight and content uniformity results. Proveris has deployed its complete solutions globally at over 60 pharmaceutical development and manufacturing sites. Proveris's complete solutions are used by the FDA and the pharmaceutical industry to set testing standards and generate robust data for their applications (please see our website www.proverisscientific.com for a list of recent publications). Proveris is certified to ISO9001:2008 by TUV Rheinland of North America and has over 15 US and internationally issued patents on it technology.
Company Contact: Zach Pitluk, Vice President of Commercialization at Proveris Scientific Corporation, (508) 460-8822 Ext. 7634, zpitluk@proverisscientific.com.
Media Contact: Lynn Blenkhorn, Feinstein Kean Healthcare, (508) 851-0930, lynn.blenkhorn@fkhealth.com.
About Pfeiffer and Valois Pharma
Valois Pharma, a division of Valois S.A.S., and Ing. Erich Pfeiffer GmbH are world leaders in nasal and pulmonary drug delivery technologies with a broad range of innovative drug delivery devices, technologies and services. Ing. Erich Pfeiffer GmbH and Valois S.A.S. are wholly owned subsidiaries of AptarGroup, Inc., a publicly traded company listed on the New York Stock Exchange (NYSE: ATR).
For further information visit www.pfeiffer-group.com or www.valoispharma.com .
8 May 2009 - Archimedes Pharma Limited announces ground breaking Phase III data showing Nasalfent to be superior to the standard of care from breakthrough cancer pain. Click here for the full press release from Archimedes Pharma Limited
9 March 2009 - Schering-Plough Corporation announced that its Board of Directors has unanimously approved a definite merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Click here for the full press release from Schering-Plough Corporation
2 March 2009 - Intranasal Therapeutics, Inc. changes name to Ikano Therapeutics and completes $9 million series B financing. Click here for the full press release from Intranasal Therapeutics, Inc .
26 February 2009 - Archimedes Pharma Limited, announces successful proof-of-concept results on two intranasal development projects. Click here for the full press release from Archimedes Pharma Limited
22 December 2008 - NovaDel Pharma Inc., announces that it has received FDA approval of Zolpimist™ 5 mg and 10 mg oral spray for short-term treatment of insomnia characterized by difficulties with sleep initiation. The active ingredient in the product is the same as the active ingredient in Sanofi Aventis's Ambien ® product, the patent for which expired on April 21, 2007. The Zolpimist™ product uses NovaDel's proprietary NovaMist™ oral spray technology. Click here for the full press release from NovaDel Pharma Inc.
17 October 2008 - Meda AB
17 October 2008 - Meda AB, announces FDA approval of Astepro ® nasal spray, a new formulation of Astelin for treatment of seasonal allergic rhinitis. The active ingredient in the product is azelastine, the leading antihistamine in the treatment of rhinitis in the U.S. Click here for the full press release from Media AB .
9 October 2008 - Archimedes Pharma Limited, announces positive Phase III results for NasalFent ® nasal spray for cancer pain. The fentanyl citrate nasal spray treats breakthrough cancer pain - unpredictable, sudden intense pain that affects the majority of cancer patients. Click here for the full press release from Archimedes Pharma .
Proveris Scientific UK Limited
November 2008, Proveris Scientific Corporation (Proveris) announces the opening of a UK based office. Proveris Scientific UK Limited (Proveris UK), a wholly-owned subsidiary of Proveris Scientific Corporation, will support Proveris’s growing customer base in Europe and Asia. Proveris UK has hired Ivan Prince to manage its service and support operations. Mr. Prince brings to the position his experience as both a scientist and system engineer for Respironics. Proveris welcomes Mr. Prince and invites its customers in Europe and Asia to contact him with service and support questions. Proveris UK is located at 1000 Lakeside, North Harbour, Western Road, Portsmouth PO6 3EZ.